Zenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.
Hamza Nazir, MBBS
Advertisement
Articles by Hamza Nazir, MBBS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
2
Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer
3
FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer
4
FDA Accepts sNDA for Taletrectinib in ROS1-Positive NSCLC
5